INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary DR. PATRICK SOON-SHIONG TO GIVE KEYNOTE ADDRESS AND NANTKWEST TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH 2016 HEALTH CARE CONFERENCE
Culver City, May 6, 2016 -- NantKwest, Inc (Nasdaq:NK), today announced that Dr. Patrick Soon-Shiong, NantKwest's Chairman and CEO will be giving the Keynote address and NantKwest will be presenting at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, Nevada on Tuesday,
View HTML
Toggle Summary NantKwest to Present Data on the First Next Generation GMP-Grade NK Cell Line for Combination Immunotherapy with Rituximab, Trastuzumab, and Daratumumab at Upcoming AACR Cancer Conference
Positive Preclinical Data Of The First “Off The Shelf,” GMP-Grade, IL-2-Independent NK Cell Line Expressing The High-Affinity Fc-Receptor To Augment Antibody Therapeutics CULVER CITY, Calif.  –  April 15, 2016  - NantKwest Inc.
View HTML
Toggle Summary NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies
Culver City, California, April 5, 2016 —NantBioScience, Inc., is a biopharmaceutical company focused on the discovery of innovative treatments by developing molecularly targeted drugs, based on the molecular profile of the patient’s tumor, independent of the cancer’s anatomical type.
View HTML
Toggle Summary Partnership enables rapid and efficient start-up of 15,000 research sites nationwide
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020 , the nation's most comprehensive cancer collaborative initiative formed to accelerate next-generation immunotherapy in cancer, announced today the selection of Schulman IRB as its national institutional review board (IRB) of record.
View HTML
Toggle Summary NantKwest and NantHealth to Present at the Cowen and Company’s 36th Annual Healthcare Conference View HTML
Toggle Summary San Diego key part of program to beat cancer by 2020
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes (/staff/bradley-fikes/) | 3:33 p.m. March 3, 2016 If physician turned billionaire biotech entrepreneur Dr. Patrick Soon-Shiong succeeds in his ambitious goal to defeat cancer by 2020, San Diego County's
View HTML
Toggle Summary Patrick Soon-Shiong, MD, to Deliver Cancer Moonshot 2020 Keynote at Biocom Global Life Science Partnering Conference
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks , LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science
View HTML
Toggle Summary Nant Leaders to Share Vision of Cancer Moonshot 2020 Program at Premier Oncology Event
Dr. Patrick Soon-Shiong keynotes on breakthroughs in immuno-oncology including development of Genomic Proteomic Sequencing test for cancer (GPS Cancer) Phoenix – February 22, 2016 – NantWorks , LLC, NantKwest (Nasdaq: NK), and NantHealth , LLC  today announced the scheduled discussion topics
View HTML
Toggle Summary NantKwest to Host Investor Day on January 14, 2016
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, announced today that
View HTML
Toggle Summary NantKwest Added to Nasdaq Biotechnology Index
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 18, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
View HTML